I trust the board knows when is the best time to approach big pharma and we have a guidance that this process will be later this calendar year. Just to have a conversation here I am just wondering if we will have enough info from the trials that have been kicked off or whether it will be a bit early to approach big pharma? Would we be in a bit better to start the big pharma discussions around mid-2022?
Also from a MC perspective, do we want to approach big pharma after we are say around $2Bn (SP around $14) so we could suggest decent multiples of the MC?
Again, I know we have an excellent board M&A / deal credentials but just while we are waiting for further news we could have a fireside/ lockdown chat
RAC Primer, page-465
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.080(4.89%) |
Mkt cap ! $264.2M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.63 | $1.54 | $166.5K | 104.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3707 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 4557 | 2 |
View Market Depth
| Last trade - 14.53pm 07/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |